Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system

Neuroscience

Volumn 103, Issue 2, 2001, Pages 385-394

  Gao, X ^a   Dluzen, D E ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Corpus striatum; Dopamine; Neuroprotectant; Parkinson's disease; Steroid hormone

Indexed keywords

ANTIESTROGEN; DOPAMINE; ESTRADIOL; ESTROGEN; METHAMPHETAMINE; POTASSIUM; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; FEMALE; GENDER; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OVARIECTOMY; PARKINSON DISEASE; PREMENOPAUSE; PRIORITY JOURNAL;

ANIMALS; CORPUS STRIATUM; DOPAMINE; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; METHAMPHETAMINE; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; OVARIECTOMY; SUBSTANTIA NIGRA; SYMPATHOMIMETICS; TAMOXIFEN;

EID: 0035857744     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(01)00014-8     Document Type: Article

References (67)

1. Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens
2. Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum
3. Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents
4. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters
5. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding
6. Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis
7. Oestrogens and extrapyramidal system
8. Vitamin E and other antioxidants in neuroprotection
9. Occurrence and distribution of dopamine in brain and other tissues
10. Sex steroids do not alter sex differences in tyrosine hydroxylase activity of dopaminergic neurons in vitro
11. Influence of sex, age and strain of MPTP-induced neurotoxicity
12. The influence of estrogen on monoamine oxidase activity
13. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress
14. Effect of estradiol and tamoxifen on brain membranes: Investigation by infrared and fluorescence spectroscopy
15. Inhibition of striatal dopamine transporter activity by 17beta-estradiol
16. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: Effects upon striatal dopamine release
17. Use of in vitro superfusion to assess the dynamics of striatal dopamine clearance: Influence of estrogen
18. In vitro dopamine release from the rat striatum: Diurnal rhythm and its modification by the estrous cycle
19. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine
20. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system
21. Estrogen as a modulator of striatal dopaminergic neurotoxicity
22. Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system
23. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: Implications for Parkinson's disease
24. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system
25. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice
26. The effect of ovarian steroids on the uptake of 3H-noradrenaline, 3H-dopamine and 3H-5-hydroxytryptamine by hypothalamic tissue in vitro
27. Comparisons between brain dopaminergic neurons of juvenile and aged rats: Sex-related differences
28. Nigrostriatal and mesolimbic dopaminergic activities were modified throughout the ovarian cycle of female rats
29. Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter
30. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults
31. Community networks for response to abuse outbreaks of methamphetamine and its analogs
32. Tamoxifen, raloxifene, and the prevention of breast cancer
33. Sex hormones and antioxidant status
34. Estrogen treatment of dyskinetic disorders
35. Methamphetamine-induced hyperthermia in mice: Examination of dopamine depletion and heat-shock protein induction
36. Gonadal hormones affect the hypothermia induced by serotonin1A (5-HT1A) receptor activation
37. Interactive effects of tamoxifen and estrogen upon the nigrostriatal dopaminergic system
38. Tamoxifen alters dopamine output through direct actions upon superfused corpus striatal tissue fragments
39. Interactive effects of tamoxifen and oestrogen upon the nigrostriatal dopaminergic system: Long-term treatments
40. Effects of estrogen treatment on sensorimotor task performance and brain dopamine concentrations in gonadectomized male and female CD-1 mice
41. Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice
42. Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists
43. The impact of gender and estrogen on striatal dopaminergic neurotoxicity
44. Antioxidant properties of steroids
45. Sex and estrous cycle variations of rat striatal dopamine uptake sites
46. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: Attenuation by dopamine D1 or D2 antagonists
47. Acute stimulatory effect of estradiol on striatal dopamine synthesis
48. Estrogens and dyskinesia
49. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: A review of evidence from microdialysis studies
50. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse
51. Antioxidant action of estrogens in rat hepatocytes
52. Parkinsonism after hysterectomy
53. Estrogens and the pathophysiology of Parkinson's disease
54. The effect of estrogen replacement on early Parkinson's disease
55. Estrogens and Parkinson's disease
56. Nitric oxide is a mediator of methamphetamine (METH)-induced neurotoxicity. In vitro evidence from primary cultures of mesencephalic cells
57. The effect of pregnancy in Parkinson's disease
58. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization study
59. Attenuation of dopamine uptake in vivo following priming with estradiol benzoate
60. Effects of estrogen on the basal ganglia
61. Estrogens, dopamine and dyskinesias
62. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine
63. Sexual differences in sensitivity to methamphetamine toxicity
64. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage
65. The effect of oestradiol dipropionate and progesterone on monoamine uptake in rat brain
66. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice
67. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity